Although longer-term follow-up is needed to determine the impact of immune checkpoint blockade in the neoadjuvant setting for patients with localized disease, improvement in the rate of pathologic ...

What are the main disease- and patient-related factors that you consider when selecting from the variety of approved treatment options for patients with relapsed/refractory multiple myeloma?

Patients who achieved a pathologic complete response after neoadjuvant therapy had better survival outcomes than patients who received adjuvant therapy.

In the years since targeted treatments for CLL were introduced, their use in the second line has increased, but chemotherapy regimens remain the most common first-line treatment in these patients.

The FDA has approved Tagrisso (osimertinib)​ to treat patients with unresectable, stage III, EGFR-mutant NSCLC whose disease has not progressed during or after chemoradiotherapy.

The incidence of cardiovascular disease is higher in older adults with cancer, especially those with hematologic, lung, and metastatic cancers.

(HealthDay News) — Most Americans don’t plan to get vaccinated against the flu or COVID-19 this season, according to a survey from the National Foundation for Infectious Diseases (NFID).

In the past 2 decades, the standard treatment approach for patients with desmoid tumors has shifted from a surgical approach to an emphasis on observation followed by systemic therapies for ...